Risk of New Primary Cancer in Patients with Posterior Uveal Melanoma: A National Cohort Study

Studies on the risk of new primary cancer in patients with posterior uveal melanoma (UM) have produced conflicting results, and the role of socioeconomic status (SES) is unknown. The purpose of this population-based matched cohort study was to determine the risk of new primary cancer following the d...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-01, Vol.14 (2), p.284
Main Authors: Bagger, Mette, Albieri, Vanna, Hindso, Tine Gadegaard, Wadt, Karin, Heegaard, Steffen, Andersen, Klaus Kaae, Kiilgaard, Jens Folke
Format: Article
Language:English
Subjects:
BRCA1 protein
Chromosomes
Cohort analysis
Confidence intervals
Diagnosis
Medical prognosis
Melanoma
Mesothelioma
Metastasis
Mortality
Patients
Population studies
Renal cell carcinoma
Risk factors
Skin cancer
Socioeconomic factors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Studies on the risk of new primary cancer in patients with posterior uveal melanoma (UM) have produced conflicting results, and the role of socioeconomic status (SES) is unknown. The purpose of this population-based matched cohort study was to determine the risk of new primary cancer following the diagnosis of posterior UM. 2179 patients with posterior UM 1968-2016 and 22,717 matched controls without cancer were included. Incidence and time-dependent hazard ratio (HR) of new primary cancer were described, and the effect of SES was emphasized in a sub-cohort. The incidence of new primary cancer was increased in patients with posterior UM, rate ratio (RR) 1.21 (95% CI: 1.08; 1.35), but the specific cancer types did not differ compared to the controls. The rate of new primary cancer following the diagnosis of posterior UM was significantly increased 2-5 years (HR 1.49 (95% CI: 1.23; 1.80)) and 11-15 years (HR: 1.49 (95% CI: 1.12; 1.99)), and adjusting for SES did not change the rate (HR 1.35 (95% CI:1.20; 1.55)). Patients with posterior UM have an increased risk of new primary cancer independent of SES. No difference in incidence of specific cancer type was observed compared to the control group.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14020284